20 Years of Producing the Highest Quality, Most Reliable, and Effective LED mask.
“A beard offers both protective and aesthetic advantages,” explains Dave Harvey, M.D. “It shields the skin from wind, chafing, and minor trauma, while also serving as a popular style statement—so we’re seeing more men maintain some form of facial hair.”
Well-groomed beards can:
Without meticulous hygiene, facial hair can harbor microbes and trigger inflammatory conditions.
“Inadequate cleansing allows sebum, yeast, and keratinous debris to accumulate, producing beard dandruff,” warns Dr. Harvey. “Patients present with erythematous, scaly periorificial plaques that respond to topical antifungal shampoos containing ketoconazole or selenium sulfide.”
Ingrown hairs may evolve into acne keloidalis nuchae—firm, keloidal papules along the posterior neck. “We manage these lesions with topical clindamycin, retinoids, or intralesional corticosteroids to reduce fibrosis,” he notes.
Low-level laser therapy (LLLT) is an FDA-cleared, non-invasive modality that delivers coherent red/infrared photons (630–680 nm) to the scalp or face. The energy is absorbed by cytochrome c oxidase within follicular mitochondria, up-regulating adenosine triphosphate (ATP) and nitric oxide release. This vasodilatory cascade increases perifollicular perfusion, transitions miniaturized hairs into anagen, and extends the growth phase—yielding measurable increases in beard density within 12–16 weeks of consistent treatment.
LLLT is also marketed as red light therapy or photobiomodulation; devices range from diode combs to flexible LED face masks.
By augmenting cellular respiration and microcirculation, LLLT reactivates dormant follicular units that have entered telogen or miniaturization pathways.
Several randomized, sham-controlled trials support LLLT for androgenetic alopecia. The National Institutes of Health have catalogued multiple laser hair growth therapy investigations demonstrating statistically significant increases in terminal hair density for both sexes without serious adverse events.
A 2013 NIH-sponsored clinical trial concluded that LLLT is a safe, effective intervention for male and female pattern hair loss.
Further reading:
A 2013 randomized controlled trial enrolled men aged 18–48 with androgenetic alopecia; after 16 weeks of low-level laser therapy (LLLT), mean terminal hair density rose by 39 % compared with baseline.
Nevertheless, LLLT is only one variable in the multifactorial pathogenesis of progressive hair loss. Key contributors include:
Clinically perceptible improvement typically emerges after 4–6 weeks of consistent red-light irradiation (2–3 sessions per week). Continued treatment for at least 90 days is recommended before reassessing efficacy; absence of regrowth at that juncture suggests poor individual responsiveness, warranting dermatologic re-evaluation and possible adjunctive strategies.
Further reading:
